SCHEMBL23768964

SCHEMBL23768964

CCOC(=O)c1cc(Cc2ccc(N3CC4CC4C3)nc2C=O)no1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 10/20 0.41
PDE10A Q9Y233 1/20 0.32
MAPT P10636 2/20 0.31
PIK3CA P42336 1/20 0.31
LMNA P02545 1/20 0.31
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
TRPA1 O75762 1/20 0.31
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
HCRTR1 O43613 1/20 0.30
HCRTR2 O43614 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23768962 0.88 KLKB1 (0.34) KLKB1PDE10AMAPTPIK3CALMNA
SCHEMBL23769304 0.88 KLKB1 (0.39) KLKB1PDE10AMAPTLMNANPSR1
SCHEMBL23768922 0.88 KLKB1 (0.41) KLKB1PDE10AMAPTLMNAHTT
SCHEMBL29906637 0.88 KLKB1 (0.41) KLKB1PDE10AMAPTLMNAHTT
SCHEMBL23768910 0.88 KLKB1 (0.41) KLKB1PDE10AMAPTPIK3CATRPA1
SCHEMBL23769298 0.87 KLKB1 (0.41) KLKB1PDE10AMAPTPIK3CAHTT
SCHEMBL23769404 0.85 KLKB1 (0.40) KLKB1PDE10AMAPTPIK3CALMNA
SCHEMBL23769693 0.81 OGA (0.38) KLKB1PIK3CA
SCHEMBL23769694 0.77 KLKB1 (0.39) KLKB1PDE10APIK3CATRPA1KDM4E
SCHEMBL23769260 0.76 ALDH1A1 (0.48) KLKB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-09-23 US disclosed
WO-2021160718-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 KLKB1 1/4885PDE10A 3529/4885MAPT 3934/4885
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors KLKB1, KLK5, KLK1 KLKB1 1/4885PDE10A 3529/4885MAPT 3934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.